Search company, investor...

Tessera Therapeutics

Founded Year



Series C | Alive

Total Raised


Last Raised

$300M | 1 yr ago

About Tessera Therapeutics

Tessera Therapeutics is an early-stage life science company pioneering Gene Writing, a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Tessera Therapeutics was founded in 2018 and is based in Cambridge, Massachusetts.

Headquarters Location

55 Cambridge Parkway Suite 800E

Cambridge, Massachusetts, 02142,

United States

Missing: Tessera Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Tessera Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Tessera Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tessera Therapeutics is included in 3 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Unicorns- Billion Dollar Startups

1,215 items


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Latest Tessera Therapeutics News

Tessera Therapeutics Frequently Asked Questions (FAQ)

  • When was Tessera Therapeutics founded?

    Tessera Therapeutics was founded in 2018.

  • Where is Tessera Therapeutics's headquarters?

    Tessera Therapeutics's headquarters is located at 55 Cambridge Parkway, Cambridge.

  • What is Tessera Therapeutics's latest funding round?

    Tessera Therapeutics's latest funding round is Series C.

  • How much did Tessera Therapeutics raise?

    Tessera Therapeutics raised a total of $530M.

  • Who are the investors of Tessera Therapeutics?

    Investors of Tessera Therapeutics include Altitude Life Science Ventures, Alaska Permanent Fund, SoftBank , Longevity Vision Fund, T. Rowe Price and 11 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.